MX2010006092A - Biomarcadores para monitorear el tratamiento mediante compuestos de quinazolinona. - Google Patents

Biomarcadores para monitorear el tratamiento mediante compuestos de quinazolinona.

Info

Publication number
MX2010006092A
MX2010006092A MX2010006092A MX2010006092A MX2010006092A MX 2010006092 A MX2010006092 A MX 2010006092A MX 2010006092 A MX2010006092 A MX 2010006092A MX 2010006092 A MX2010006092 A MX 2010006092A MX 2010006092 A MX2010006092 A MX 2010006092A
Authority
MX
Mexico
Prior art keywords
treatment
biomarkers
monitoring
quinazolinone compounds
quinazolinone
Prior art date
Application number
MX2010006092A
Other languages
English (en)
Inventor
Peter H Schafer
Justin B Bertlett
Ling-Hua Zhang
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of MX2010006092A publication Critical patent/MX2010006092A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4727—Calcium binding proteins, e.g. calmodulin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4739—Cyclin; Prad 1

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

En la presente se provee biomarcadores para monitorear el tratamiento mediante compuestos de quinazolinona. Por ejemplo, se provee el uso de SPARC, p21, y niveles de mARN de ciclina DI como biomarcadores para predecir si un compuesto de quinazolinona puede tener éxito para tratar ciertos tipos de cáncer, tales como NHL. Además, la expresión de estos genes se puede usar para monitorear el progreso de efectividad del tratamiento y el cumplimiento de pacientes en pacientes con cáncer que reciben tratamiento con compuestos de quinazolinona.
MX2010006092A 2007-12-07 2008-12-05 Biomarcadores para monitorear el tratamiento mediante compuestos de quinazolinona. MX2010006092A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US580407P 2007-12-07 2007-12-07
PCT/US2008/013444 WO2009075795A1 (en) 2007-12-07 2008-12-05 Biomarkers for monitoring the treatment by quinazolinone compounds

Publications (1)

Publication Number Publication Date
MX2010006092A true MX2010006092A (es) 2010-07-05

Family

ID=40430210

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010006092A MX2010006092A (es) 2007-12-07 2008-12-05 Biomarcadores para monitorear el tratamiento mediante compuestos de quinazolinona.

Country Status (6)

Country Link
US (1) US20110111396A1 (es)
EP (1) EP2232267A1 (es)
JP (1) JP2011505807A (es)
CA (1) CA2707729A1 (es)
MX (1) MX2010006092A (es)
WO (1) WO2009075795A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2013010153A (es) * 2011-03-11 2013-09-26 Celgene Corp Metodos de tratamiento del cancer utilizado 3 - (5 - amino- 2 - metil - 4 - oxo - 4h - quinazolin - 3 - il) - piperidin - 2, 6 - diona.
KR102014478B1 (ko) * 2017-05-12 2019-08-26 한국화학연구원 신규한 피페리딘-2,6-디온 유도체 및 이의 용도

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8420603B2 (en) * 2004-05-14 2013-04-16 Abraxis Bioscience, Llc SPARC and methods of use thereof
US7553496B2 (en) * 2004-12-21 2009-06-30 University Of Kentucky Research Foundation VEGF-A as an inhibitor of angiogenesis and methods of using same
AU2006236557A1 (en) * 2005-04-14 2006-10-26 Novartis Vaccines And Diagnostics Inc. 2-amino-quinazolin-5-ones as HSP90 inhibitors useful in treating proliferation diseases

Also Published As

Publication number Publication date
US20110111396A1 (en) 2011-05-12
EP2232267A1 (en) 2010-09-29
WO2009075795A1 (en) 2009-06-18
CA2707729A1 (en) 2009-06-18
JP2011505807A (ja) 2011-03-03

Similar Documents

Publication Publication Date Title
MY150797A (en) Combination therapies comprising quinaxoline inhibitors of pi3k-alpha for use in the treatment of cancer
MY183661A (en) Treatment of cancer with tor kinase inhibitors
MX2019005130A (es) Inhibidores de dpp-iv, tales como la linagliptina, y composiciones farmaceuticas o combinaciones que comprenden los mismos, para usarse en el tratamiento de pacientes diabeticos tipificados geneticamente.
TN2012000450A1 (en) Biomarkers for mdm2 inhibitors for use in treating disease
MX2010006090A (es) Biomarcadores para predecir la sensibilidad de las celulas ante compuestos inmunomoduladores durante el tratamiento de linfoma de no hodgkin.
NZ585209A (en) Micro-rnas of the mir-15 family modulate cardiomyocyte survival and cardiac repair
ECSP11010971A (es) Tratamiento de la diabetes en pacientes con control glucemico insuficiente a pesar de la terapia con un fármaco oral o no oral antidiabético
MY188365A (en) Diagnosis and treatments relating to th2 inhibition
TN2013000508A1 (en) Combination therapy comprising a cdk4/6 inhibitor and a pi3k inhibitor for use in the treatment of cancer
HK1139863A1 (en) Methods of treating cancer using pyridopyrimidinone inhibitors of pi3k alpha
NZ590550A (en) Inhibitors of Apoptosis (IAP) for treating cancer
MX341896B (es) Biomarcadores para el tratamiento de psoriasis.
MY178012A (en) Treatment of cancer with tor kinase inhibitors
SG10201810575WA (en) Treatment of prostate cancer with tor kinase inhibitors
UA106214C2 (ru) Ингибиторы митоза для интенсификации процесса апоптоза при терапии
MX2010006092A (es) Biomarcadores para monitorear el tratamiento mediante compuestos de quinazolinona.
MX2016004212A (es) Inhibidor de tor cinasa en la prevencion o tratamiento de cancer caracterizado por mutaciones genicas.
AU2012346899A8 (en) Materials and methods related to NSAID chemoprevention in colorectal cancer
WO2010124239A3 (en) Genetic polymorphisms associated with clinical outcomes of topoisomerase inhibitor therapy for cancer
MX2011006532A (es) Compuestos anticancerigenos.
EA201491836A1 (ru) Способы лечения рака с использованием ингибитора pi3k и ингибитора mek
MX2013012083A (es) Biomarcadores para el tratamiento de mieloma multiple.
WO2011133479A3 (en) Combination therapy with a proteasome inhibitor and a gallium complex
TN2013000247A1 (en) Compositions comprising a pi3k inhibitor and a mek inhibitor and their use for treating cancer
WO2013040504A3 (en) Srpx for treatment of cancer

Legal Events

Date Code Title Description
FA Abandonment or withdrawal